Advertisement

Topics

Novartis' Brolucizumab Shows Dose Advantage Over Eylea In nAMD Trials

08:49 EDT 20 Jun 2017 | SCRIP

Prospects for Novartis' nAMD eye treatment brolucizumab rose on news the novel anti VEGF treatment met primary and key secondary...

      

Related Stories

 

Original Article: Novartis' Brolucizumab Shows Dose Advantage Over Eylea In nAMD Trials

NEXT ARTICLE

More From BioPortfolio on "Novartis' Brolucizumab Shows Dose Advantage Over Eylea In nAMD Trials"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...